|
Name |
Talaromycin A
|
Molecular Formula | C12H22O4 | |
IUPAC Name* |
(3R,4S,6R,9R)-9-ethyl-3-(hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-4-ol
|
|
SMILES |
CC[C@@H]1CC[C@@]2(C[C@@H]([C@@H](CO2)CO)O)OC1
|
|
InChI |
InChI=1S/C12H22O4/c1-2-9-3-4-12(15-7-9)5-11(14)10(6-13)8-16-12/h9-11,13-14H,2-8H2,1H3/t9-,10-,11+,12-/m1/s1
|
|
InChIKey |
VDWRKBZMQNPUOB-WISYIIOYSA-N
|
|
Synonyms |
Talaromycin A; 83720-10-9; (3R,4S,6R,9R)-9-ethyl-3-(hydroxymethyl)-1,7-dioxaspiro[5.5]undecan-4-ol; (-)-Talaromycin A; DTXSID90232575; CHEBI:169379; 1,7-Dioxaspiro(5.5)undecane-3-methanol, 9-ethyl-4-hydroxy-, (3R,4S,6R,9R)-
|
|
CAS | 83720-10-9 | |
PubChem CID | 158564 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 230.3 | ALogp: | 1.2 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 58.9 | Aromatic Rings: | 2 |
Heavy Atoms: | 16 | QED Weighted: | 0.751 |
Caco-2 Permeability: | -4.795 | MDCK Permeability: | 0.00003620 |
Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.898 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.224 |
30% Bioavailability (F30%): | 0.008 |
Blood-Brain-Barrier Penetration (BBB): | 0.215 | Plasma Protein Binding (PPB): | 27.19% |
Volume Distribution (VD): | 1.418 | Fu: | 55.03% |
CYP1A2-inhibitor: | 0.018 | CYP1A2-substrate: | 0.741 |
CYP2C19-inhibitor: | 0.022 | CYP2C19-substrate: | 0.82 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.056 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.211 |
CYP3A4-inhibitor: | 0.013 | CYP3A4-substrate: | 0.382 |
Clearance (CL): | 9.996 | Half-life (T1/2): | 0.679 |
hERG Blockers: | 0.12 | Human Hepatotoxicity (H-HT): | 0.225 |
Drug-inuced Liver Injury (DILI): | 0.097 | AMES Toxicity: | 0.12 |
Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.574 |
Skin Sensitization: | 0.946 | Carcinogencity: | 0.802 |
Eye Corrosion: | 0.878 | Eye Irritation: | 0.989 |
Respiratory Toxicity: | 0.571 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000928 | 1.000 | D04VIS | 0.215 | ||||
ENC004715 | 0.574 | D0HR8Z | 0.197 | ||||
ENC002228 | 0.250 | D0KR5B | 0.196 | ||||
ENC004001 | 0.250 | D0D1SG | 0.196 | ||||
ENC004545 | 0.234 | D0I1LH | 0.194 | ||||
ENC005832 | 0.229 | D0Z4EI | 0.194 | ||||
ENC005945 | 0.228 | D04QNO | 0.191 | ||||
ENC003798 | 0.225 | D0Y7IU | 0.191 | ||||
ENC002918 | 0.224 | D00ZTD | 0.190 | ||||
ENC003906 | 0.224 | D0U3CR | 0.185 |